Our Research

Our lab uses chemical approaches to control cellular systems as exemplified by the development of Proteolysis Targeting Chimeras (PROTACs) in the new field of Targeted Protein Degradation

News

Craig Crews Named Winner of 2024 Kimberly Prize

Annual biochemistry and molecular genetics award recognizes a scientist whose molecular discovery has improved human health. Read more >

Craig Crews and Ray Deshaies have been awarded the 2023 Gabbay Prize for their pioneering work in the development of PROTACs and the field of Targeted Protein Degradation.

Crews and Deshaies are trailblazers in the field of targeted protein degradation, spearheading the development of PROTACs—a revolutionary approach. Their groundbreaking research has expanded the understanding of cellular processes and opened the potential to develop innovative...

Craig is awarded the Heinrich Wielend Prize, Heinrich Wieland Laureate 2020

Thanks to the results of his many years of research, Professor Craig M. Crews of Yale University in New Haven, Connecticut, is making innovative new medicines possible. So-called PROTACs (proteolysis-targeting chimeras) activate a cell’s quality control system to target disease-causing proteins for degradation. These new active substances are intended to specifically destroy proteins that, until now, have been therapeutically impervious. For his ground-breaking research, Professor Crews has been awarded the 2020 Heinrich Wieland Prize.

Craig is awarded the 2021 Scheele Prize from the Swedish Pharmaceutical Society

Professor Craig Crews has been awarded the Scheele prize 2021 for his broad excellence in drug discovery and development spanning from molecule to patient. He has combined groundbreaking science with strong entrepreneurship and received wide international recognition for his work on pharmacological modulation of protein turnover. His findings have led to new therapeutic approaches including the development of novel proteasome inhibitors and the PROTAC technology.